Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial

Digestive and Liver Disease

Volumn 47, Issue 3, 2015, Pages 226-232

  Chen, Shihui ^a   Zhao, Xiaolan ^a   Ran, Li ^a   Wan, Jing ^a   Wang, Xiaofang ^a   Qin, Yu ^a   Shu, Furong ^a   Gao, Yanxiang ^a   Yuan, Lijia ^a   Zhang, Qianyong ^a   Mi, Mantian ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Insulin sensitivity; Metabolic syndrome; Nutrition

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; C PEPTIDE; CHOLESTEROL; CREATININE; CYTOKERATIN 18; CYTOKINE; FIBROBLAST GROWTH FACTOR 21; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; RESVERATROL; TUMOR NECROSIS FACTOR ALPHA; GLUCOSE BLOOD LEVEL; STILBENE DERIVATIVE;

ADULT; ANTHROPOMETRY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ECHOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEMOGLOBIN DETERMINATION; HUMAN; INSULIN RESISTANCE; INTENTION TO TREAT ANALYSIS; LEUKOCYTE COUNT; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MICROCAPSULE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL; BLOOD; DRUG EFFECTS; HOMEOSTASIS; LIVER; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; YOUNG ADULT;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BLOOD GLUCOSE; CHOLESTEROL; CYTOKINES; DOUBLE-BLIND METHOD; FEMALE; HOMEOSTASIS; HUMANS; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; STILBENES; YOUNG ADULT;

EID: 84924079162     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2014.11.015     Document Type: Article

References (41)

1. Matteoni C.A., Younossi Z.M., Gramilich T., et al. Non-alcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419.
2. Lonardo A., Sookoian S., Chonchol M., et al. Cardiovascular and systemic risk in non-alcoholic fatty liver disease - atherosclerosis as a major player in the natural course of NAFLD. Current Pharmaceutical Design 2013, 19:5177-5192.
3. Musso G., Gambino R., Cassader M., et al. A meta-analysis of randomized trials for the treatment of non-alcoholic fatty liver disease. Hepatology 2010, 52:79-104.
4. Nascimbeni F., Pais R., Bellentani S., et al. From NAFLD in clinical practice to answers from guidelines. Journal of Hepatology 2013, 59:859-871.
5. Ballestri S., Lonardo A., Bonapace S., et al. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World Journal of Gastroenterology: WJG 2014, 20:1724-1745.
6. Mazzella N., Ricciardi L.M., Mazzotti A., et al. The role of medications for the management of patients with NAFLD. Clinics in Liver Disease 2014, 18:73-89.
7. Brown V.A., Patel K.R., Viskaduraki M., et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Research 2010, 70:9003-9011.
8. Mukherjee S., Dudley J.I., Das D.K. Dose-dependency of resveratrol in providing health benefits. Dose-Response 2010, 8:478-500.
9. Gomez-Zorita S., Fernandez-Quintela A., Macarulla M.T., et al. Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. British Journal of Nutrition 2012, 107:202-210.
10. Shang J., Chen L.L., Xiao F.X., et al. Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacologica Sinica 2008, 29:698-706.
11. Baek S.H., Shin W.C., Ryu H.S., et al. Creation of resveratrol-enriched rice for the treatment of metabolic syndrome and related diseases. PLOS ONE 2013, 8:1-10.
12. Cho I.J., Ahn J.Y., Kim S., et al. Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters. Biochemical and Biophysical Research Communications 2008, 367:190-194.
13. Kitada M., Kume S., Imaizumi N., et al. Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway. Diabetes 2011, 60:634-643.
14. Renes J., Rosenow A., Roumans N., et al. Calorie restriction-induced changes in the secretome of human adipocytes, comparison with resveratrol-induced secretome effects. Biochimica et Biophysica Acta 2014, 1844:1511-1522.
15. Timmers S., Konings E., Bilet L., et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metabolism 2011, 14:612-622.
16. Brasnyo P., Molnar G.A., Mohas M., et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. British Journal of Nutrition 2011, 106:383-389.
17. Liu K., Zhou R., Wang B., et al. Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials. American Journal of Clinical Nutrition 2014.
18. Kim S., Jin Y., Choi Y., et al. Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice. Biochemical Pharmacology 2011, 81:1343-1351.
19. Yoshino J., Conte C., Fontana L., et al. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metabolism 2012, 16:658-664.
20. Poulsen M.M., Vestergaard P.F., Clasen B.F., et al. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 2013, 62:1186-1195.
21. Chachay V.S., Macdonald G.A., Martin J.H., et al. Resveratrol does not benefit patients with non-alcoholic fatty liver disease. Clinical Gastroenterology and Hepatology 2014.
22. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB Journal 2008, 22:659-661.
23. Centis E., Marzocchi R., Suppini A., et al. The role of lifestyle change in the prevention and treatment of NAFLD. Current Pharmaceutical Design 2013, 19:5270-5279.
24. Chiloiro M., Caruso M.G., Cisternino A.M., et al. Ultrasound evaluation and correlates of fatty liver disease: a population study in a Mediterranean area. Metabolic Syndrome and Related Disorders 2013, 11:349-358.
25. Anty R., Marjoux S., Iannelli A., et al. Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. Journal of Hepatology 2012, 57:1090-1096.
26. Farrell G.C., Larter C.Z. Non-alcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43:S99-S112.
27. Scaglioni F., Marino M., Ciccia S., et al. Short-term multidisciplinary non-pharmacological intervention is effective in reducing liver fat content assessed non-invasively in patients with non-alcoholic fatty liver disease (NAFLD). Clinics and Research in Hepatology and Gastroenterology 2013, 37:353-358.
28. Jarrar M.H., Baranova A., Collantes R., et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics 2008, 27:412-421.
29. Endo M., Masaki T., Seike M., et al. TNF-alpha induces hepatic steatosis in mice by enhancing gene expression of sterol regulatory element binding protein-1c (SREBP-1c). Experimental Biology and Medicine 2007, 232:614-621.
30. Aller R., Luis D.A., Fernandez L., et al. Influence of insulin resistance and adipokines in the grade of steatosis of non-alcoholic fatty liver disease. Digestive Diseases and Sciences 2008, 53:1088-1092.
31. Yamamoto Y., Hirose H., Saito I., et al. Adiponectin, an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population. Journal of Clinical Endocrinology and Metabolism 2004, 89:87-90.
32. Palsamy P., Subramanian S. Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling. Biochimica et Biophysica Acta - Molecular Basis of Disease 2011, 1812:719-731.
33. Wieckowska A., Zein N.N., Yerian L.M., et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in non-alcoholic fatty liver disease. Hepatology 2006, 44:27-33.
34. Malhi H., Gores G.J. Cellular and molecular mechanisms of liver injury. Gastroenterology 2008, 134:1641-1654.
35. Feldstein A.E., Wieckowska A., Lopez A.R., et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for non-alcoholic steatohepatitis: a multicenter validation study. Hepatology 2009, 50:1072-1078.
36. Nishimura T., Nakatake Y., Konishi M., et al. Identification of a novel FGF,FGF-21, preferentially expressed in the liver. Biochimica et Biophysica Acta 2000, 1492:203-206.
37. Dostálová I., Haluzíková D., Haluzík M. Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/type 2 diabetes mellitus. Physiological Research 2009, 58:1-7.
38. Chen C., Cheung B.M.Y., Tso A.W.K., et al. High plasma level of fibroblast growth factor 21 is an independent predictor of type 2 diabetes a 5.4-year population-based prospective study in Chinese subjects. Diabetes Care 2011, 34:2113-2115.
39. Dushay J., Chui P.C., Gopalakrishnan G.S., et al. Increased fibroblast growth factor 21 in obesity and non-alcoholic fatty liver disease. Gastroenterology 2010, 139:456-463.
40. Osawa H., Mori Y. Sonographic diagnosis of fatty liver using a histogram technique that compares liver and renal cortical echo amplitudes. Journal of Clinical Ultrasound: JCU 1996, 24:25-29.
41. Hernaez R., Lazo M., Bonekamp S., et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011, 54:1082-1090.